Alpha(1,3)-galactosyltransferase null cells, methods of selecting and alpha(1,3)-galactosyl transferase null swine produced therefrom
AssigneeImmerge Biotherapeutics, Inc.
InventorRobert Hawley
Life of this patent
Estimating the term…
Abstract
The invention relates to the genetic manipulation of non-human animals. More particularly, the invention relates to genetic manipulation of non-human animals to be used for xenotransplantation. The invention provides a method of selecting GGTA 1 null cells, a viable GGTA 1 null swine, methods for making such swine, and methods of using cells, tissues and organs of such swine for xenotransplantation.
Claims43
A viable GGTA1 null swine.
A method of selecting GGTA1 null cells comprising the steps of:
- (a) obtaining a line of cells obtained from a GGTA1 heterozygous pig or fetus;
- (b) enriching the cells for GGTA1 null cells;
- and
- (c) scanning the line for viable GGTA1 null cells.
The method according to any of 4-6, wherein the gal epitope ligands are IB4 conjugates and the anti-epitope ligands are anti-IB4 conjugates.
A porcine GGTA1 null cell.
A porcine organ lacking expression of galactose-α(1,3)-galactose epitopes.
Porcine tissues lacking expression of galactose-α1,3-galactose epitopes.
A method of creating a viable GGTA1 null swine comprising selecting GGTA1 null cells, enucleating an oocyte, fusing the oocyte with the said GGTA1 null cell to yield an NT-derived embryo, and implanting the NT-derived embryo into a surrogate mother, wherein the surrogate mother has initiated estrus, but has not yet completed ovulation.
Dependencies are inferred from the claim text.